{"prompt": "['5. STUDY DESIGN', '5.1. Safety run-in', '1st step:', '5 patients will be included first according to the following treatment regimen:', 'FOLFIRI + durvalumab', 'FOLFIRI', 'Irinot\u00e9can : 180 mg/m\u00b2 par perfusion IV de 2 heures.', 'cycle', 'I', 'Acide Folinique: 400 mg/m\u00b2 (ou 200 mg/m\u00b2 si', 'Elvorine) par perfusion IV de 2 heures.', '5FU-bolus: 400 mg/m\u00b2 par bolus IV de 10 minutes.', '5-FU continu: 2400 mg/m\u00b2 par perfusion IV de 46', 'heures.', 'wo', 'W4', 'W8', 'W12', 'One cycle every 4 weeks', '8', 'Durvalumab : 1500 mg en 1 heure - perfusion IV', '2nd step:', '6 patients (3 patients per arm) will be randomized according to the following treatment regimen:', 'FOLFIRI durvalumab', 'FOLFIRI', 'Irinotecan : 180 mg/m\u00b2 by 2-hours IV infusion.', '1 cycle', 'Folinic Acid : 400 mg/m\u00b2 (or 200 mg/m\u00b2 if', 'Elvorine) by 2-hours IV infusion.', '5FU-bolus: 400 mg/m\u00b2 by 10-minutes IV bolus.', 'Continuous 5-FU: 2400 mg/m2 by 46-hours IV', 'infusion.', 'wo', 'W4', 'One cycle every 4 weeks', '8', 'Durvalumab: 1500 mg by 1-hour IV infusion', 'R', 'FOLFIRI* + durvalumab + tremelimumab', 'If progression', 'FOLFIRI*', '1 cycle', '1 cycle', '1 cycle', 'Irinotecan 150 by 2-hours IV infusion.', 'Folinic Acid 400 mg/m\u00b2 (or 200 mg/m\u00b2 if', 'Elvorine) by 2-hours IV infusion.', '5FU-bolus: 400 mg/m\u00b2 by 10-minutes IV bolus.', 'Continuous 5-FU: 2400 mg/m\u00b2 by 46-hours IV', 'infusion.', 'wo', 'W4', 'W8', 'W12', 'W16', 'Durvalumab 1500 mg by 1-hour - IV infusion', 'One cycle every 4', 'One cycle', 'One cycle every 4 weeks', 'weeks', 'every 4', 'For 4 cycles', 'Tremelimumab : 75 mg by 1-hour IV infusion', 'Untillprogression', 'weeks', 'Tremelimumab is administered for 4 cycles (4 months) and then patient will continue to receive FOLFIRI plus', 'durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control, tremelimumab can be re-', 'introduced at investigator discretion for 4 courses. Only one re-introduction is authorized.', 'Patient must have 2 weeks of washout period of first-line treatment before treatment in the trial (4 weeks if', 'investigational product in first-line setting, previous immunotherapy is not allowed). Treatment will be repeated', \"every 4 weeks until disease progression, unacceptable toxicity or patient's refusal.\", '5.2. Phase II study', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 18 de 123']['Arm A (experimental arm) :', 'FOLFIRI + durvalumab', 'cycle', 'wo', 'W4', 'One cycle every 4 weeks', 'R', 'Arm B (experimental arm) :', 'FOLFIRI + durvalumab + tremelimumab', 'If progression', '1 cycle', '1 cycle', '1 cycle', 'wo', 'W4', 'W8', 'W12', 'W16', 'One cycle every 4', 'One cycle', 'One cycle every 4 weeks', 'weeks', 'every 4', 'For 4 cycles', 'Untill progression', 'weeks', 'FOLFIRI', 'Irinotecan : 180 mg/m\u00b2 by 2-hours IV infusion.', 'Folinic Acid : 400 mg/m\u00b2 (or 200 mg/m\u00b2 if', 'Tremelimumab : 75 mg by 1-hour IV infusion', 'Elvorine) by 2-hours IV infusion.', '5FU-bolus: 400 mg/m\u00b2 by 10-minutes IV bolus.', '8', 'Durvalumab : 1500 mg by 1-hour - IV infusion', 'Continuous 5-FU: 2400 mg/m\u00b2 by 46-hours IV', 'infusion.', 'In arm B: Tremelimumab is administered for 4 cycles (4 months) and then patient will continue to receive', 'FOLFIRI plus durvalumab. In case of progression on FOLFIRI plus durvalumab and disease control,', 'tremelimumab can be re-introduced at investigator discretion for 4 courses. Only one re-introduction is', 'authorized.', 'Patient must have 2 weeks of washout period of first-line treatment before treatment in the trial (4 weeks if', 'investigational product in first-line setting, previous immunotherapy is not allowed). Treatment will be repeated', \"every 4 weeks until disease progression, unacceptable toxicity or patient's refusal.\", '6. TREATMENTS', 'Both durvalumab and tremelimumab will be provided by FFCD whereas 5-FU, folinic acid and irinotecan will', 'be sampled on commercial stock.', '6.1. Description, packaging and labeling of durvalumab', 'Durvalumab will be supplied by FFCD as a 500-mg vial solution for infusion after dilution.', 'The solution contains 50 mg/mL durvalumab, 26 mM histidine/histidine hydrochloride, 275 mM trehalose', 'dihydrate, and 0.02% weight/volume (w/v) polysorbate 80; it has a pH of 6.0. The nominal fill volume is 10.0', 'mL.', 'Investigational product vials are stored at 2\u00b0C to 8\u00b0C and must not be frozen. Drug product should be kept in', 'secondary packaging until use to prevent excessive light exposure.', \"The dose of durvalumab for administration must be prepared by the Investigator's or site's designated\", 'investigational product manager using aseptic technique. Total time from needle puncture of the durvalumab', 'vial to the start of administration should not exceed:', '24 hours at 2\u00b0C to 8\u00b0C', '4 hours at room temperature', 'Infusion solution must be allowed to equilibrate to room temperature prior to commencement of administration.', 'A dose of 1500 mg (for patients >30kg in weight) will be administered using an IV bag containing 0.9% (w/v)', 'PRODIGE 59 - DURIGAST -', 'Version 2.0 - 04.08.2020 ENG', 'Page 19 de 123']\n\n###\n\n", "completion": "END"}